Moreover, CTLA-4 inhibitors commonly cause colitis, pituitary inflammation, and rashes, whereas PD-(L)1 inhibitors were more likely to casuse pneumonia, hypothyroidism, arthralgia and vitiligo (26). This evidence concerns the gene CTLA4 and colitis.